Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
matthew.edmans@ndm.ox.ac.uk

Research groups

Klenerman Group

Matthew Edmans

Postdoctoral Scientist

Recent publications

The development of a pan-genotypic T cell vaccine against hepatitis C virus using heterologous prime-boost strategies.

Strain R. et al, (2025), Hepatology

MAIT cell-MR1 reactivity is highly conserved across multiple divergent species.

Edmans MD. et al, (2024), J Biol Chem, 300

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.

Wellens J. et al, (2022), Gut, 71, 1919 - 1922

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

McNaughton AL. et al, (2022)

Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients.

Youngs J. et al, (2021), PLoS Pathog, 17

More publications